Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when ...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/d1997be7-6c53-467b-8817-7fbb39b1e7ac)